mRNA Covid-19 Booster

Will Quince Excerpts

Friday 17th March 2023 Commons Chamber

[The Minister for Health and Secondary Care (Will Quince)]

As the hon. Member for North West Leicestershire (Andrew Bridgen) says, I am responding on behalf of the Under-Secretary of State for Health and Social Care, my hon. Friend the Member for Lewes (Maria Caulfield).

Vaccines have underpinned the Government’s strategy for living with covid-19. They have saved tens of thousands of lives, have reduced the pressure on our NHS and were instrumental in allowing our economy and society to reopen. Covid-19 has not gone away. Thousands of people in the United Kingdom continue to be infected each week. Vaccines remain our best line of defence and the most effective way to enable us to live with the virus. Countless studies have shown that vaccinated people are less likely to die or become seriously ill from the virus. Thanks to the huge efforts of NHS staff and the public, as of 5 March, 144 million vaccine doses had been provided in England alone. That includes more than 17 million in the recent autumn booster campaign, which concluded last month.

The hon. Gentleman referred to the efficacy of the mRNA covid-19 boosters. It is important to put on record that all the vaccines used in the UK covid-19 vaccination programme have been through a vigorous approval process. The UK has some of the highest safety standards in the world, and the independent Medicines and Healthcare products Regulatory Agency is globally recognised for requiring high standards of quality, safety and effectiveness. The mRNA covid-19 boosters approved for use in the United Kingdom have also been through similar rigorous approval processes by the European Medicines Agency in Europe and the Food and Drug Administration in the United States.

Each potential covid-19 vaccine is assessed by teams of scientists and clinicians on a case-by-case basis. There are extensive checks and balances required by law at every stage of vaccine development. Only once each potential vaccine has met robust standards of quality, safety and efficacy set by the MHRA will it be approved for use. Both the mRNA and non-mNRA vaccines have already been administered as booster doses, with the majority of doses administered in the recent autumn booster being the mRNA vaccine. Data shows that covid-19 boosters have been highly effective in reducing hospitalisations and deaths. The mortality rate has been significantly lower for people who have had at least a third dose or booster dose, compared with individuals who are unvaccinated, or have received just a first or second dose.

Earlier this month, the Office for National Statistics published its latest covid-19 effectiveness estimates, which showed that, between March ’21 and March ’22, a third booster dose was approximately 93% effective at reducing the risk of mortality from covid-19, compared with 58% for a first dose and 88% for a second dose. It was 77% effective at reducing the risk of hospitalisation, compared with 52% for a first dose and 55% for the second dose. That highlights the effectiveness of all covid-19 vaccinations and shows that protection only increases following a third dose or booster. This is supported by other extensive research such as UK Health Security Agency surveillance reports.

The most recent data from UKHSA on the autumn 2022 booster campaign showed that the mRNA bivalent boosters provided incremental protection against hospitalisations on top of the protection already provided by previous doses in the period following 5 September 2022. It also showed that effectiveness against hospitalisation remained high at 10 or more weeks after vaccination, which was vital in supporting the NHS over a particularly challenging winter period.

The hon. Gentleman raised the matter of ongoing vaccine surveillance. The surveillance of vaccines does not stop at the point of approval. The MHRA and the UK Health Security Agency continuously monitor a wide range of data regarding the safety and effectiveness of the vaccines, including reports, as he pointed out, of adverse reactions from the UK and internationally. As part of this surveillance, the MHRA’s monitoring role includes reviewing all suspected adverse drug reaction reports—known as yellow card reports—relating to covid-19 vaccines. Through the MHRA yellow card scheme, members of the public and healthcare professionals can report any suspected side effects. The nature of yellow card reporting means that reported events are not always proven side effects; some events may have happened anyway, regardless of vaccination. This comprehensive surveillance strategy alerts us to any unforeseen adverse reactions to the vaccines and enables us to act swiftly when required.

The Government are also committed to further research into covid vaccines. Since the start of the pandemic, the National Institute for Health and Care Research has allocated more than £110 million in funding for covid-19 vaccine research. That has included consideration of vaccine safety, including robust monitoring of adverse reactions to covid-19 vaccines.

In summary, we know that the covid vaccine programme has saved tens of thousands of lives and has prevented many more hospitalisations. The Government have recently announced that a targeted seasonal vaccination offer will come in on 17 April in England to top up the protection of those at highest risk. Vaccination of residents in older adult care homes will start ahead of that, from Monday 3 April. The primary aim of the spring programme continues to be the prevention of severe disease, hospitalisations and death. Older persons, residents in care homes for older adults and those who are immunosuppressed continue to be at the highest risk of severe covid-19 and are therefore prioritised for vaccination.

The covid vaccine programme is something of which this country can be very proud. I reiterate my thanks to the scientists, clinical staff, volunteers and others who have helped to make it happen.

Question put and agreed to.